Sensei Biotherapeutics (NASDAQ:FTH) Receives “Buy” Rating from HC Wainwright

Sensei Biotherapeutics (NASDAQ:FTH)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $60.00 target price on the stock. HC Wainwright’s target price points to a potential upside of 110.01% from the stock’s previous close.

FTH has been the subject of a number of other reports. Zacks Research raised shares of Sensei Biotherapeutics to a “hold” rating in a research note on Tuesday, April 21st. Citizens Jmp initiated coverage on shares of Sensei Biotherapeutics in a research note on Monday, July 20th. They set an “outperform” rating and a $51.00 target price on the stock. JonesTrading assumed coverage on Sensei Biotherapeutics in a report on Tuesday, August 4th. They set a “buy” rating and a $55.00 target price on the stock. Citigroup started coverage on shares of Sensei Biotherapeutics in a research note on Friday, May 22nd. They set a “buy” rating and a $55.00 price objective for the company. Finally, Raymond James Financial began coverage on Sensei Biotherapeutics in a research note on Friday, July 31st. They issued an “outperform” rating and a $56.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $54.90.

Sensei Biotherapeutics Trading Up 17.1%

FTH stock opened at $28.57 on Tuesday. Sensei Biotherapeutics has a 1 year low of $7.21 and a 1 year high of $37.90. The firm has a market capitalization of $38.28 million, a price-to-earnings ratio of -0.20 and a beta of -0.25.

Sensei Biotherapeutics (NASDAQ:FTH) last released its quarterly earnings results on Friday, May 15th. The company reported ($131.45) EPS for the quarter. As a group, analysts predict that Sensei Biotherapeutics will post -13.18 EPS for the current year.

Insider Activity

In related news, major shareholder James Peyer sold 25,000 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $20.02, for a total transaction of $500,500.00. Following the completion of the transaction, the insider owned 130,142 shares of the company’s stock, valued at approximately $2,605,442.84. The trade was a 16.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Brian C. Stephenson bought 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were bought at an average price of $23.50 per share, with a total value of $117,500.00. Following the completion of the purchase, the chief financial officer owned 46,688 shares in the company, valued at approximately $1,097,168. The trade was a 11.99% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have acquired 49,494 shares of company stock valued at $1,188,822. 7.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Sensei Biotherapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its stake in Sensei Biotherapeutics by 10.6% during the fourth quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock valued at $123,000 after acquiring an additional 1,100 shares during the period. Bank of America Corp DE increased its position in shares of Sensei Biotherapeutics by 10,692.5% during the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares during the period. Stempoint Capital LP bought a new position in Sensei Biotherapeutics in the first quarter worth $4,188,000. Finally, Vivo Capital LLC bought a new stake in Sensei Biotherapeutics in the 1st quarter valued at $22,758,000. 10.50% of the stock is owned by institutional investors and hedge funds.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.